This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rapp, U R Articles by Bister, K Search for Related Content PubMed PubMed Citation Articles by Rapp, U R Articles by Bister, K

 Previous Article  |  Next Article 

J Virol. 1985 July; 55(1): 23-33

Rapid induction of hemopoietic neoplasms in newborn mice by a raf(mil)/myc recombinant murine retrovirus.

ABSTRACT

3611 MSV, a raf oncogene-transducing murine retrovirus, induced fibrosarcomas in newborn mice after a latency of 4 to 8 weeks. In contrast, newly constructed recombinant murine retroviruses carrying the myc oncogene did not induce tumors before greater than or equal to 9 weeks. A combination of both oncogenes in an infectious murine retrovirus induced hematopoietic neoplasms in addition to less prominent fibrosarcomas and pancreatic acinar dysplasia 1 to 3 weeks after inoculation. The hematological neoplasms consisted of immunoblastic lymphomas of T- and B-lineage cells and erythroblastosis. Cell lines from these tumors could be readily established in culture in regular medium, whereas culture of cells from raf oncogene-induced tumors required the addition of interleukin 3. In parallel to the synergistic action of both oncogenes on hematopoietic cells in vivo, we found that raf oncogene-induced transformation of fibroblast cell lines in culture was enhanced by the addition of myc, which by itself did not morphologically transform these permanent cell lines. We conclude that concomitant expression of raf and myc oncogenes in hematopoietic cells and fibroblastic cell lines enhances their respective transforming activities.

This article has been cited by other articles:

• Delabesse, E., Ogilvy, S., Chapman, M. A., Piltz, S. G., Gottgens, B., Green, A. R. (2005). Transcriptional Regulation of the SCL Locus: Identification of an Enhancer That Targets the Primitive Erythroid Lineage In Vivo. Mol. Cell. Biol. 25: 5215-5225 [Abstract] [Full Text]  
• Fedorov, L. M., Papadopoulos, T., Tyrsin, O. Y., Twardzik, T., Gotz, R., Rapp, U. R. (2003). Loss of p53 in craf-induced Transgenic Lung Adenoma Leads to Tumor Acceleration and Phenotypic Switch. Cancer Res. 63: 2268-2277 [Abstract] [Full Text]  
• Coghill, E., Eccleston, S., Fox, V., Cerruti, L., Brown, C., Cunningham, J., Jane, S., Perkins, A. (2001). Erythroid Kruppel-like factor (EKLF) coordinates erythroid cell proliferation and hemoglobinization in cell lines derived from EKLF null mice. Blood 97: 1861-1868 [Abstract] [Full Text]  
• Lin, S.-C., Wortis, H. H., Stavnezer, J. (1998). The Ability of CD40L, but Not Lipopolysaccharide, To Initiate Immunoglobulin Switching to Immunoglobulin G1 Is Explained by Differential Induction of NF-kappa B/Rel Proteins. Mol. Cell. Biol. 18: 5523-5532 [Abstract] [Full Text]  
• Nadler, M. J. S., Chen, B., Anderson, J. S., Wortis, H. H., Neel, B. G. (1997). Protein-tyrosine Phosphatase SHP-1 Is Dispensable for Fcgamma RIIB-mediated Inhibition of B Cell Antigen Receptor Activation. J. Biol. Chem. 272: 20038-20043 [Abstract] [Full Text]  
• Luscher, B, Eisenman, R N (1990). New light on Myc and Myb. Part I. Myc.. Genes Dev. 4: 2025-2035  
• Lieber, M R, Hesse, J E, Mizuuchi, K, Gellert, M (1987). Developmental stage specificity of the lymphoid V(D)J recombination activity.. Genes Dev. 1: 751-761 [Abstract]  
• Potter, M, Mushinski, J., Mushinski, E., Brust, S, Wax, J., Wiener, F, Babonits, M, Rapp, U., Morse, H. 3rd (1987). Avian v-myc replaces chromosomal translocation in murine plasmacytomagenesis. Science 235: 787-789 [Abstract]  
• Weinberg, R. (1985). The action of oncogenes in the cytoplasm and nucleus. Science 230: 770-776 [Abstract]  
• Jin, L., McLean, P. A., Neel, B. G., Wortis, H. H. (2002). Sialic Acid Binding Domains of CD22 Are Required For Negative Regulation of B Cell Receptor Signaling. J. Exp. Med. 195: 1199-1205 [Abstract] [Full Text]